全身MRI中ADC测量的重复性与再现性:一项前瞻性多中心研究
本研究在三个中心使用相同3.0-T扫描仪的前瞻性多中心研究中,测试标准化全身MRI方案(含DWI),每中心入组8名健康志愿者,在同一中心进行测试与重测、并在另一中心进行第三次检查。ADC变异不受中心或阅片者影响,仅受器官影响;基于重复性与再现性系数95%CI上限,提出各器官ADC变化需超过12%至94%不等才具有显著性。
要点
- 全身MRI标准化方案下,ADC变异仅受器官影响,不受采集中心或阅片者影响。
- 脑白质ADC变化需超过12%、肝35%、脾45%、前列腺中央带及外周带26%才认为显著。
- 骨结构ADC重复性较差:股骨需超过68%、L5椎体66%、髋臼94%的变化才显著。
核心结论
- 本研究提出在多中心全身MRI试验中,ADC变化需超过各器官特定的重复性与再现性上限,才可作为评估疾病或治疗相关组织微结构变化的可靠定量终点。
研究设计与样本
- 前瞻性多中心研究,在三个配备相同3.0-T扫描仪的中心进行,测试包含扩散加权成像的全身MRI方案。
- 每个中心入组8名健康志愿者,接受同中心测试与重测检查,以及另一中心的第三次检查。
- 由两名阅片者使用双因素混合方差分析、Bland-Altman图、变异系数及重复性系数与再现性系数95%CI上限评估多器官ADC变异性。
关键影像表现/征象
- ADC的变异系数除器官外不受中心或阅片者等其他因素影响。
诊断标准与关键数值
- 基于两名阅片者重复性系数与再现性系数95%CI上限,个体患者ADC变化需超过12%(脑白质)才显著。
- ADC变化需超过16%(椎旁肌)、22%(肾皮质)、26%(前列腺中央带及外周带)、29%(肾髓质)才显著。
- ADC变化需超过35%(肝)、45%(脾)、50%(髂后嵴)、66%(L5椎体)、68%(股骨)、94%(髋臼)才显著。
临床应用与阅片要点
- 在标准化全身MRI方案且使用同型MRI扫描仪的多中心框架下,可依据上述器官特异性阈值判断ADC变化是否具有临床意义。
- 判读ADC变化时应考虑器官差异,骨结构阈值明显高于脑白质、肝、脾等器官。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Multicenter oncology trials increasingly include MRI examinations with apparent diffusion coefficient (ADC) quantification for lesion characterization and follow-up. However, the repeatability and reproducibility (R&R) limits above which a true change in ADC can be considered relevant are poorly defined. This study assessed these limits in a standardized whole-body (WB)-MRI protocol.
METHODS: A prospective, multicenter study was performed at three centers equipped with the same 3.0-T scanners to test a WB-MRI protocol including diffusion-weighted imaging (DWI). Eight healthy volunteers per center were enrolled to undergo test and retest examinations in the same center and a third examination in another center. ADC variability was assessed in multiple organs by two readers using two-way mixed ANOVA, Bland-Altman plots, coefficient of variation (CoV), and the upper limit of the 95% CI on repeatability (RC) and reproducibility (RDC) coefficients.
RESULTS: CoV of ADC was not influenced by other factors (center, reader) than the organ. Based on the upper limit of the 95% CI on RC and RDC (from both readers), a change in ADC in an individual patient must be superior to 12% (cerebrum white matter), 16% (paraspinal muscle), 22% (renal cortex), 26% (central and peripheral zones of the prostate), 29% (renal medulla), 35% (liver), 45% (spleen), 50% (posterior iliac crest), 66% (L5 vertebra), 68% (femur), and 94% (acetabulum) to be significant.
CONCLUSIONS: This study proposes R&R limits above which ADC changes can be considered as a reliable quantitative endpoint to assess disease or treatment-related changes in the tissue microstructure in the setting of multicenter WB-MRI trials.
KEY POINTS: • The present study showed the range of R&R of ADC in WB-MRI that may be achieved in a multicenter framework when a standardized protocol is deployed. • R&R was not influenced by the site of acquisition of DW images. • Clinically significant changes in ADC measured in a multicenter WB-MRI protocol performed with the same type of MRI scanner must be superior to 12% (cerebrum white matter), 16% (paraspinal muscle), 22% (renal cortex), 26% (central zone and peripheral zone of prostate), 29% (renal medulla), 35% (liver), 45% (spleen), 50% (posterior iliac crest), 66% (L5 vertebra), 68% (femur), and 94% (acetabulum) to be detected with a 95% confidence level.
引用
- Michoux NF, Ceranka JW, Vandemeulebroucke J, et al. Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study. Eur Radiol. 2021. PMID: 33409773. doi:10.1007/s00330-020-07522-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。